Growth Hormone Therapy in Children: Unanswered Questions on Musculoskeletal Safety, Long-Term Outcomes, and Precision Monitoring
Key Insights
Growth hormone therapy is widely used for pediatric growth disorders, but long-term safety—particularly musculoskeletal complications—remains an area of active investigation.
Reported musculoskeletal adverse events include slipped capital femoral epiphysis, scoliosis progression, joint pain, and transient bone or muscle discomfort, with risk factors still poorly defined.
Researchers are calling for standardized frameworks for musculoskeletal monitoring, risk stratification models, and multidisciplinary preventive care approaches.
Growth hormone (GH) therapy has transformed the care of children with growth hormone deficiency (search), Turner syndrome (search), Prader–Willi syndrome (search), children born small for gestational age (search), and other growth disorders. While its effectiveness in promoting linear growth is well established, clinicians increasingly recognize that successful treatment extends beyond height alone—encompassing metabolic balance and quality of life. Yet as more children receive growth hormone for longer durations, and as long-acting formulations become available for certain indications, significant questions about safety and long-term outcomes remain unanswered.
Growing Concerns Over Musculoskeletal Safety
Reported musculoskeletal complications associated with GH therapy include slipped capital femoral epiphysis, progression of scoliosis, joint pain, and transient bone or muscle discomfort. Although large-scale clinical trials and registries suggest that GH therapy is generally safe when appropriately managed, heterogeneity in patient response and a lack of predictive markers highlight the need for targeted risk assessment.
Contemporary studies are increasingly drawing on real-world data to uncover previously under-recognized adverse patterns and to refine understanding of safety across diverse pediatric cohorts. Nonetheless, standardized frameworks for musculoskeletal monitoring, early detection of complications, and multidisciplinary preventive care remain insufficiently defined.
Unanswered Questions Driving Research Agendas
Despite ongoing research, several critical questions remain unresolved. Which children are at higher risk for adverse musculoskeletal outcomes? How should monitoring differ among different underlying disorders and age groups? What is the safety profile of long-acting growth hormone formulations? Can artificial intelligence help in predicting adverse outcomes? And how does treatment with growth hormone therapy affect children and their families beyond the scope of growth?
These questions are now being prioritized in research agendas aimed at deepening understanding of the safety and musculoskeletal effects of GH therapy in pediatric patients. Investigators are integrating evidence from clinical studies, observational registries, and real-world practice to improve identification of risk factors, enhance monitoring strategies, and optimize multidisciplinary management models that safeguard musculoskeletal health during treatment.
Long-Term Outcomes Beyond Height
Long-term outcomes extending into adulthood remain an active area of investigation. Questions persist regarding metabolic health, cardiovascular risk, bone quality, neurocognitive development, safety, adherence, and cost-effectiveness. In parallel, advances in long-acting formulations, precision dosing strategies, and real-world registry data are reshaping clinical practice and offering opportunities to optimize individualized treatment approaches.
Researchers are particularly interested in comparative evaluation of daily versus long-acting growth hormone formulations, as well as metabolic, skeletal, and cardiovascular outcomes during and after GH therapy. The transition from pediatric to adult care following GH therapy also represents an important focus area, with registry data playing a key role in tracking lifelong health trajectories.
Toward Precision Endocrinology
The field is moving toward precision endocrinology approaches that integrate mechanistic insights with real-world clinical evidence. Themes of interest include treatment optimization through dosing strategies, IGF-1 (search) monitoring, and individualized response prediction. Pharmacogenomics and evolving therapeutic formulations are also being explored as tools to support evidence-based decision-making in pediatric growth disorders.
By bringing together clinicians, researchers, allied health professionals, and patient advocates, the research community aims to inform approaches that ultimately improve lifelong health trajectories for affected children and adolescents. The integration of digital health and remote monitoring, patient-reported outcomes, and quality-of-life measures linked to growth and musculoskeletal well-being are increasingly recognized as essential components of comprehensive care.